The efficacy of methotrexate (MTX) as a single graftversus-host disease (GVHD) prophylaxis agent was compared to that of cyclosporin A (CSA) in 62 pediatric patients (median age: 8 years) with hematological malignancies who had undergone bone marrow transplantation (BMT) from HLA-identical sibling donors at National Kyushu Cancer Center since 1977. In all, 30 patients received MTX by intravenous bolus injection, with a dose of 15 mg/m 2 on day +1, followed by 10 mg/m 2 on days +3, +6, and +11, and then once a week until day +100. A total of 32 patients were treated with CSA, which was given intravenously in the early stages and orally thereafter until day +100, and then gradually tapered and stopped 6 months after BMT. There were no differences between the groups in terms of rates of hematopoietic recovery after BMT. The probabilities of acute GVHD (grades II-IV) and chronic GVHD were 29.6 vs 40.6% (P ¼ 0.294) and 19 vs 20% (MTX vs CSA), respectively. Relapse rates and event-free survival were identical. These results suggest that MTX and CSA were equally effective when given after BMT in Japanese pediatric patients with hematological malignancies. Since MTX was given over a shorter time than CSA, it might be more practical in the management of such patients.
laxis; pediatric patients; Japanese Graft-versus-host disease (GVHD) is a major predictor of outcome following allogeneic bone marrow transplantation (BMT). Its prevention and control have been the most important factors in providing patients with a normal quality of life after BMT. Since hematopoietic stem cell transplantation including BMT has become a routine clinical procedure in most centers, there have been many reports regarding the prophylaxis or treatment of acute and chronic GVHD based upon clinical experience. 1 However, the number of prophylaxis regimens is limited in practice to a combination of cyclosporin A (CSA) or tacrolimus (FK506) with methotrexate (MTX). Thus, regimens including CSA or FK506 plus short-term MTX (sMTX) have become established for this purpose in adults, even with unrelated donors. 2, 3 In a pediatric population, the probability of acute GVHD did not differ between single or combined prophylaxis regimens. 4 Furthermore, Locatelli et al. 5 confirmed in a prospective randomized study that the use of low-dose CSA (1 mg/kg/day) gave a better survival rate than regular-dose CSA (3 mg/kg/day) as a single prophylactic agent in patients with hematological malignancies. 5 To elucidate the details of the mechanism of GVHD, several investigators have reported data in animal models and multicenter randomized clinical trials to evaluate the effectiveness of GVHD prophylaxis regimens. However, there is still a lack of data in pediatric patients, who usually have a different incidence and severity of GVHD than adult patients.
We report on the effectiveness of MTX and CSA as single agents for GVHD prophylaxis in pediatric patients. We examined the results at a single center and conducted a long-term follow-up in a Japanese pediatric population. Table 1 shows the characteristics of 62 pediatric patients with malignant hematological disorders. They were transplanted from HLA-identical sibling donors at National Kyushu Cancer Center between 1977 and 2000. MTX alone was given to 30 patients and CSA was given to 32. The median age and body weight in the MTX and CSA groups were identical (8 vs 8 years, 23.2 vs 27.2 kg).
Patients and methods

Patients
Of the 30 children in the MTX group, 17 had standardrisk features including acute lymphoblastic leukemia (ALL) in the first or second complete remission (CR), acute myeloblastic leukemia (AML) in first CR, or refractory anemia (RA) with myelodysplastic syndrome (MDS). A total of 13 patients had high-risk features such as Xthird CR in ALL or refractory phase (RP), AML in Xsecond CR or RP, acute unclassified leukemia, chronic myelocytic leukemia in second chronic phase, or MDS other than RA. Of the 32 children in the CSA group, 22 had standard and 20 had high-risk features. As of December 2001, the median follow-up duration was 78 (19-296) months in the MTX group and 129 (21-220) months in the CSA group.
HLA-typing of the donors and recipients was performed by serology. Previous chemotherapy regimens varied because the patients were each treated by the protocol at their referring institute.
Pretransplant regimens
The conditioning regimens are described in Tables 1 and 2 . Those with lymphoid malignancies received total body irradiation (TBI)-based regimens and those with myeloid malignancies were treated with non-TBI regimens. As an exception, before 1988 we used a TBI-containing regimen for patients with AML. Only one patient with ALL was treated with a non-TBI regimen in this study.
Bone marrow aspiration and cell processing
Bone marrow nucleated cells (BMNC) were aspirated using an Isram biopsy needle from the posterior iliac crest under general anesthesia in the operating room. In some donors, BMNC were also aspirated from the anterior iliac crest. The target dose of BMNC was 3-4 Â 10 8 /kg of the recipient's body weight. Red blood cells (RBC) were depleted from 21 grafts because of ABO-major mismatch and from one because of minor mismatch. In two cases, plasma exchange was performed just before BMT to reduce the titer of anti-A or -B antigen because of minor mismatch.
GVHD prophylaxis and treatment
In our center, two drugs were used for prophylaxis of GVHD after the introduction of CSA in 1986. Before that, MTX was routinely used as a single prophylaxis agent according to the reported method. 6 When we adopted melphalan (L-PAM) as a drug for conditioning, we preferred using MTX for GVHD prophylaxis based on consideration of the renal toxicity of the drug. MTX was given intravenously as a bolus injection at a dose of 15 mg/ m 2 on day +1, followed by 10 mg/m 2 on days +3, +6, and +11, and then once a week until day +100, in principle. None of the patients received folic acid as a rescue for mucositis. In the early 1990's, if there was no sign of GVHD by day +30 in patients with high-risk features, we stopped MTX. When patients developed acute GVHD of grade II or more, prednisolone was started, and when it had a noticable effect, MTX was discontinued as GVHD prophylaxis before day +100 with the continuation of On the other hand, CSA was administered intravenously from day À1 at 3 mg/kg/day divided into two doses over 1 h. 7 The trough level was thereafter maintained between 150 and 250 ng/ml for the first 4 weeks, when renal function was not impaired. The target trough level of CSA after 4 weeks was between 100 and 200 ng/ml. Using this method, the actual dose of CSA was between 2 and 5 mg/kg/day. In the absence of chronic GVHD, CSA was gradually tapered from day +100 and was discontinued 3 months later, in principle. Diagnoses of acute and chronic GVHD were based on clinical and/or histological findings as described by Glucksberg et al 8 and Shulman et al 9 respectively. Biopsy of skin or oral mucosa was performed as necessary from 1988.
Oral prednisolone (2 mg/kg/day) was used as the first choice of treatment for acute and chronic GVHD in these patients. It was continued for 2-4 weeks depending on the response rate, and then tapered by 0.5 mg/kg/2-4 weeks. If the patient could not take oral medications, soluble prednisolone or methylprednisolone were used instead.
Supportive care
The actual method of supportive therapy has changed based on the development or improvement of new drugs and equipment including a WBC-trapping filter, an irradiation system for blood products, and antifungal or antibacterial agents. In principle, all of the patients were nursed in a filtered laminar airflow single room and managed with mask and glove isolation. A combination of vancomycin, amphotericin B and polymyxine B was given for gut decontamination. All of the patients received intravenous hyperalimentation and transfusion of blood products when needed. Blood products were irradiated to 15 Gy and filtered to deplete contaminating WBC, except for the sole case before 1985. Acyclovir was administered at 5-7.5 mg/kg intravenously every 12 h from day À7 to +28. Intravenous gamma-globulin 250-400 mg/kg was given weekly or biweekly until day +100, and monthly thereafter until 6 months to 1 year, if necessary. In some cases after 1989, granulocyte colony-stimulating factor (G-CSF: filgrastim, Sankyo Co., Tokyo or lenograstim, Chugai Co., Tokyo) was given intravenously at a dose of 300 mg/m 2 or 5 mg/m 2 over 1 h from day +5 or +7.
Engraftment rate
The engraftment rates of neutrophils and platelets were determined by the number of days to achieve an absolute neutrophil count (ANC) of 40.5 Â 10 9 /l and a platelet count of 50 Â 10 9 /l, respectively, without transfusions. The last day that transfusion was required was also evaluated.
Statistics
To compare patient characteristics, the Mann-Whitney U-test and w 2 test were used where appropriate. The probability of hematopoietic recovery, probabilities of acute and chronic GVHD, rates of relapse and survival were calculated using the Kaplan-Meier method and by taking censored observations into account. Differences between the groups were evaluated with the logrank test. The relations between G-CSF, CSA, or MTX, and neutrophil recovery was evaluated by the Cox proportionalhazard model.
Results
Cell doses and complications
The median number of BMNC in the graft was 4. Two of 30 patients in the MTX group died from sepsis because of bacteremia on days 9 and 11 before engraftment. A total of nine patients had urinary tract complications, including hemorrhagic cystitis (HC) that developed in eight patients (one in MTX and seven in CSA). In two of these seven in the CSA group, adenovirus was identified from the urine. There was no relation between the development of HC and the type of pretransplant regimen. Two of the seven patients with HC in the CSA group suffered from pyelonephritis or renal dysfunction.
Engraftment
Two of the 62 grafts were rejected. In one patient, the graft was a primary rejection. In the other case, neutrophil engraftment was confirmed on day 29, but the numbers gradually declined thereafter, and rejection was finally confirmed on day 109. Both rejections were in the MTX group.
Engraftment data are shown in Table 3 . The median number of days to achieve an ANC of 40.5 Â 10 9 /l after BMT in the MTX and CSA groups was 17 and 15, respectively (P ¼ 0.919). The recovery patterns of ANC and platelets were identical between the groups by a log-rank test, as shown in Figure 1 . Since 22 patients in the MTX group and 18 in the CSA group were treated with G-CSF from day +5 or +7 after BMT, the effect of G-CSF administration was evaluated by multivariate analysis with a Cox hazard model. The use of G-CSF accelerated engraftment rate, with a hazard ratio of 4.4 (95% CI, 2.2-8.8, Po0.001). On the other hand, CSA was superior to MTX with regard to enhancement of the engraftment rate, with a hazard ratio of 2.2 (95% CI, 1.2-4.1, P ¼ 0.011). The median number of days to achieve a platelet count of 450 Â 10 9 /l was 26 in both groups (P ¼ 0.635).
The median number of days to achieve a reticulocyte count of 410% was 19 in the MTX group and 25 in the CSA group (P ¼ 0.608). There were no differences in the last day of transfusion of platelets or RBC products.
GVHD
In a total of 27 patients in the MTX group, the development of acute GVHD was analyzed, and seven patients continued to receive MTX up to day +100 according to the protocol. In all, 20 patients stopped receiving MTX before day +100, since this was not needed to treat GVHD in 12 patients and prednisolone was replaced by MTX to treat acute GVHD (grade XII) in eight patients. MTX was discontinued on a median of day +60 (range 30-100) and the median number of doses received was 11 (range 7-16). On the other hand, three of 32 patients stopped receiving CSA before day +100, since they had no GVHD and were at a high risk of relapse. The probability of acute GVHD (any grade) was not significantly different between the groups (59.3% in MTX vs 75.0% in CSA; P ¼ 0.056). Acute GVHD requiring treatment (grade XII) occurred in 29.6% (MTX) and 40.6% (CSA), and these values were also statistically identical (P ¼ 0.294). The probability of acute GVHD (grade XII) is shown in Figure 2 (upper panel) . The probability of acute GVHD (grade III) in the MTX group (6.7%) was not significantly different from that in the CSA group (0.12%) (P ¼ 0.43). None of the patients in either group showed acute GVHD of grade IV. A total of 21 patients (8 in MTX, 13 in CSA) were treated for acute Upper and lower panels show the cumulative probability of neutrophil recovery (40.5 Â 10 9 /l) and platelet recovery (450 Â 10 9 /l), respectively. There were no significant differences between the groups by the logrank test. The thin and thick line indicate the data for the MTX and CSA groups, respectively. and lower panels show the cumulative incidence of acute GVHD (grade 4II) and chronic GVHD (limited or extensive), respectively. There were no significant differences between the groups by the logrank test. The thin and thick lines indicate the data for the MTX and CSA groups, respectively. GVHD (grade 4II) with prednisolone according to the protocol, and none of these patients failed to respond.
On the other hand, a total of 56 patients (26 in MTX, 30 in CSA) survived more than 100 days and were evaluated for the probability of chronic GVHD. Chronic GVHD (either limited or extensive) developed in 19% of patients on MTX and 20% of those on CSA. This difference was not significant (P ¼ 0.999) (Figure 2, lower panel) . They also responded to prednisolone therapy, as did those with acute GVHD (grade XII).
A total of 14 patients with standard-risk AML received MTX and 13 with standard-risk ALL received CSA. The probabilities of acute GVHD (grades II-IV) in these two groups were 21 and 31%, respectively (P ¼ 0.57). Chronic GVHD was seen in 29 and 23% of the patients, respectively (P ¼ 0.66).
Relapse rate
Probability of relapse was calculated by the logrank test. Relapse rates were 32.6% in the MTX group and 38.0% in the CSA group (P ¼ 0.502). When the analysis was limited to standard-risk patients, the relapse rates were 23.3% with MTX and 32.4% with CSA (P ¼ 0.400). The relapse rate for high-risk patients was 50.0% in both groups (P ¼ 0.849). Thus, there were no significant differences in relapse rates between the study groups ( Figure 3) .
The Kaplan-Meier estimates of relapse rates in 14 standard-risk AML patients in the MTX group and 13 standard-risk ALL patients in the CSA group were 14 and 48%, respectively, which were statistically identical (P ¼ 0.08).
Survival
The principal causes of death are shown in Table 4 . Relapse was the most frequent cause of death. In particular, all of the deaths in the CSA group were because of relapse. The Kaplan-Meier estimates of event-free survival (EFS) rates were 50% in the MTX group and 62% in the CSA group, which were not significantly different (P ¼ 0.400) (Figure 3 ). The EFS rates of standard-risk patients were 67.1% in the MTX group and 67.6% in the CSA group (P ¼ 0.898), while those of high-risk patients were 31.0% in the MTX group and 50.0% in the CSA; again, this difference was not significant (P ¼ 0.323).
Discussion
The main cause of GVHD has been thought to be the incompatibility of major HLA antigens, and the matching of major HLA is the most important procedure in allogeneic HSCT. 10, 11 Recently, disparity in the minor antigen system has been speculated to contribute to the probability and severity of GVHD in HSCT from major antigen-matched donors. 12 However, this still cannot explain all cases of GVHD perhaps because of the small number of minor antigens that have to date been discovered.
In this study, the median follow-up duration was significantly different (MTX; 78 months (19-296) vs CSA; 129 (21-220)), since CSA was used more frequently than MTX after the introduction of CSA in the 1980's. There were more long-term survivors in the CSA than the MTX group, since four early cases in the MTX group who were treated before 1989 did not survive. Thereafter, we used CSA in patients who received a non-L-PAM regimen and MTX in those who received an L-PAM-containing conditioning regimen based on a consideration of its renal toxicity. There seems to be more ALL in the CSA group and more AML (CR1) in the MTX group. However we considered that differences in this distribution between the study groups would have no effect on relapse rate or GVHD. In fact, there were no differences in relapse rate or probability of GVHD between AML with MTX and ALL with CSA. Since we treated and followed the patients for a long time in this study, we cannot neglect the influence of a time effect. For instance, patients with AML had previously received BMT in the first remission, while few such patients now receive BMT at such a time point. Thus, no definitive conclusion regarding DFS can be drawn from this study.
The risk of GVHD in a pediatric population has been thought to be lower than that in adults, and GVHD prophylaxis with a single agent has been sufficient to prevent it, based on historical experience. 5 Recently, several high-quality studies have been conducted, including a two and lower two curves show the probability of event-free survival and relapse, respectively, in both groups. There were no significant differences between the groups by the log-rank test. The thin and thick lines indicate the data for the MTX and CSA groups, respectively. prospective randomized trial in a pediatric population to show the usefulness of a prophylaxis regimen with CSA alone in the treatment of hematological malignancies. 5 Under these circumstances, we retrospectively analyzed the effects of MTX and CSA as single agents in GVHD prophylaxis in pediatric patients who had undergone BMT from an HLA-identical sibling donor at a single institute. In this study, we found no significant difference in the incidence of acute GVHD grades II-IV or any type of chronic GVHD between the study groups (MTX group; 28.3 and 19% vs CSA group; 44 and 20%, respectively). These data correspond to those from Europe reported by Locatelli et al. 5 As we expected, the incidence of acute and chronic GVHD prevented by a single agent, CSA or MTX, was lower than that in adults, as reported by Storb et al, 13 whereas there was no difference in the prophylactic effects of CSA and MTX even in an adult population.
The mechanism that causes GVHD is complex. 14 It may involve not only genetic heterogeneity but also other factors including patient and/or donor age, or the prophylaxis regimen. For example, the regimen of CSA plus sMTX that was established by the Seattle group has been shown to be superior to a single-agent regimen by a prospective randomized study. 15 Furthermore, tacrolimus, which is a stronger immune suppressor, has been confirmed to be superior to CSA+sMTX in an adult population, 16 but not in a pediatric population. 17 Thus, differences in a pediatric population should be considered when applying routine clinical management.
The disadvantages of MTX over CSA were delayed recovery of hematopoiesis 18 and severe mucositis in the early days of HSCT. 19 Both can be overcome by the administration of G-CSF, as shown in this study, and the use of folic acid, as reported elsewhere. 19 Furthermore, fine dose adjustment is not required with the use of MTX.
Our results suggest that single-agent prophylaxis with MTX or CSA was sufficient in the setting of pediatric BMT from an HLA-identical sibling donor. Although both drugs can be stopped earlier than the day expected by the protocol in this setting, GVHD prophylaxis with MTX may be simpler and more practical in this population.
